Clinical Research Directory

Inclusion Criteria: Subjects will be considered eligible for participation in the study if they meet all the following inclusion criteria: 1. Adult patients age of 18-85 (had 18th birthday but did not have 85th birthday). 2. History of COVID 19 infection established by positive polymerase chain reaction (PCR) test or by compatible clinical testing (e.g. rapid antigen, serum testing, or other relevant clinical documentation). 3. Persistent symptoms for 12 or more weeks after acute COVID 19 infection including fatigue and one or more of the following: myalgia or generalized aches and pains; joint pain; dizziness or unsteadiness; cognitive dysfunction (mental fog). 4. Patient (legally designated representative) has completed the Informed Consent process prior to enrollment into this study. 5. Patient (legally designated representative) is willing to comply with the study protocol - Exclusion Criteria: Subjects meeting any of the following criteria will not be recruited for the study: 1. History of heparin allergy. 2. History of heparin-induced thrombocytopenia. 3. Pregnancy or breastfeeding. 4. Life expectancy is less than 30 days. 5. The patient is currently enrolled in another drug or device trial. Patients who cannot tolerate placement of double-lumen catheter. 6. Unable to obtain informed consent from either patient or legally authorized representative (LAR)Any subject who, in the investigator's judgment, is considered unsuitable for participation in this trial. After verification of eligibility and signature of consent: 1\. The patient must be able to perform a hemoperfusion procedure with an apheresis machine.